InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,144.00
(
-0.16%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.47
(
0.34%
)
Bitcoin
60,871.36
(
-1.52%
)
Post# of 252385
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: None

Friday, 12/02/2016 1:07:54 PM

Friday, December 02, 2016 1:07:54 PM

Post# of 252385
ABIO / Blade:

Bristow is a legit name in CV. The bucindolol program may have a chance, but I'm generally negative on these subgroup-driven trials.

Also keep in mind that unlike other beta-blockers, bucindolol failed to improve survival versus placebo. This may be reflective of the patient populations they studied, or of the fact that bucindolol is a slightly weaker blocker than the others.

Nonetheless, this type of thing isn't my cup of tea.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up